戻る Agenda
Session 4: Where and When Should We be Measuring?
Session Chair(s)
Cynthia Grossman, PHD
Director, Science of Patient Input, FasterCures, A Center of the Milken Institute, United States
Learning Objective : At the conclusion of this session, participants should be able to:- Identify the specific time points along the product lifecycle where patient engagement could be measured
- Define at least three issues to consider related to the timing measurement of PE appropriately
- Give one example of how the measurement of PE would differ depending on timing of the product lifecycle
Speaker(s)
Mathieu Boudes, PHD
Patient Engagement Director, Montsouris Consilium, France
Where and When Should We be Measuring?
Bray Patrick-Lake, MS
Senior Digital Health Specialist, DDH, CDRH, FDA, United States
Measuring the Value & Impact of Patient Engagement in Clinical Trials
James Valentine, JD, MHS
Director, Hyman, Phelps & McNamara, PC, United States
Measuring Impact in Patient Engagement: Regulatory Opportunities